Dr Brian Donnelly, MD in Clinton, NJ - Radiology

Dr Brian Donnelly, MD is a Radiology - Diagnostic Radiology physician based in Clinton, New Jersey. Dr Brian Donnelly is licensed to practice in New Jersey (license number MA25850) and his current practice location is 1 Dogwood Drive, Clinton, New Jersey. He can be reached at his office (for appointments etc.) via phone at (908) 806-2700.

NPI number for Dr Brian Donnelly is 1538157094 and his current mailing address is Po Box 5388, Clinton, New Jersey. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1538157094.

Contact Information

	Dr Brian Donnelly, MD
	1 Dogwood Drive, Clinton, NJ 08809-0388
	(908) 806-2700
	(908) 806-2525

Physician's Profile

Full Name	Dr Brian Donnelly
Gender	Male
Speciality	Radiology - Diagnostic Radiology
Location	1 Dogwood Drive, Clinton, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1538157094
Provider Enumeration Date: 10/10/2005
Last Update Date: 01/25/2013

Medical Identifiers

Medical identifiers for Dr Brian Donnelly such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1538157094	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2085R0202X	Radiology - Diagnostic Radiology	MA25850 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Brian Donnelly is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Brian Donnelly, MD Po Box 5388, Clinton, NJ 08809-0388 Ph: (908) 806-2700	Dr Brian Donnelly, MD 1 Dogwood Drive, Clinton, NJ 08809-0388 Ph: (908) 806-2700

News Archive

Explicit differences exist between meditation techniques

As doctors increasingly prescribe meditation to patients for stress-related disorders, scientists are gaining a better understanding of how different techniques from Buddhist, Chinese, and Vedic traditions produce different results.

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

Researchers recommend action to reverse federal court decision on embryonic stem cell research ban

Against a backdrop of some of the world's most sophisticated biological research labs, Rep. Steve Israel (D-Huntington) this morning issued a challenge to his colleagues in Congress immediately upon their return from summer recess, he urged, they should pass legislation that would reverse a recent Federal court decision that has brought embryonic stem cell research in the U.S. to a screeching halt.

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

Penn study has implications for developing new cell-based treatments for skin disease

As the main component of connective tissue in the body, fibroblasts are the most common type of cell. Taking advantage of that ready availability, scientists from the Perelman School of Medicine at the University of Pennsylvania, the Wistar Institute, Boston University School of Medicine, and New Jersey Institute of Technology have discovered a way to repurpose fibroblasts into functional melanocytes, the body's pigment-producing cells.

Dr Brian Donnelly, MD - Radiology in Clinton, NJ